Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2026	Dec. 31, 2025
Current Assets
Cash	$ 6,088,085	$ 5,334,322
Advances on research and development contract services	208,972	208,972
Prepaid insurance	63,745	232,946
Other prepaid expenses	10,000	10,000
Deferred offering costs	52,666
Interest receivable	8,977	9,895
Total current assets	6,432,445	5,796,135
Total assets	6,432,445	5,796,135
Current Liabilities
Accounts payable and accrued expenses	480,577	417,884
Warrant liability	198	703
Total current liabilities	480,775	418,587
Total liabilities	480,775	418,587
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at September 30, 2026 and December 31, 2025
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 3,389,057 and 1,795,260 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	3,389	1,795
Additional paid-in capital	96,235,991	93,506,122
Accumulated deficit	(90,287,710)	(88,130,369)
Total stockholders’ equity	5,951,670	5,377,548
Total liabilities and stockholders’ equity	$ 6,432,445	$ 5,796,135

Advances on research and development contract services.

No definition available.

Name:	BBLG_AdvancesOnResearchAndDevelopmentContractServices
Namespace Prefix:	BBLG_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.